126 related articles for article (PubMed ID: 34092344)
1. Participant-funded clinical trials on rare diseases.
Dal-Ré R; Palau F; Guillén-Navarro E; Ayuso C
An Pediatr (Engl Ed); 2020 Oct; 93(4):267.e1-267.e9. PubMed ID: 34092344
[TBL] [Abstract][Full Text] [Related]
2. [Participant-funded clinical trials on rare diseases].
Dal-Ré R; Palau F; Guillén-Navarro E; Ayuso C
An Pediatr (Engl Ed); 2020 Oct; 93(4):267.e1-267.e9. PubMed ID: 32499195
[TBL] [Abstract][Full Text] [Related]
3. A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial.
Masters A; Nutt D
J Med Ethics; 2017 Nov; 43(11):730-736. PubMed ID: 28588147
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the evolution in the access to orphan medicines in Spain].
Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
[TBL] [Abstract][Full Text] [Related]
5. [Which efficacy trials for drugs for rare diseases?].
Traversa G; Trotta F
Epidemiol Prev; 2017; 41(5-6):318-319. PubMed ID: 29119773
[No Abstract] [Full Text] [Related]
6. Permitting patients to pay for participation in clinical trials: the advent of the P4 trial.
Shaw D; de Wert G; Dondorp W; Townend D; Bos G; van Gelder M
Med Health Care Philos; 2017 Jun; 20(2):219-227. PubMed ID: 27757784
[TBL] [Abstract][Full Text] [Related]
7. Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs.
Bannister JB
Fordham Law Rev; 2018 Mar; 86(4):1889-921. PubMed ID: 29993206
[TBL] [Abstract][Full Text] [Related]
8. Legal issues surrounding privately funded research cause furore in Toronto.
Shuchman M
CMAJ; 1998 Oct; 159(8):983-6. PubMed ID: 9834727
[TBL] [Abstract][Full Text] [Related]
9. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
10. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
11. Children's views on taking medicines and participating in clinical trials.
Nordenmalm S; Kimland E; Ligas F; Lehmann B; Claverol J; Nafria B; Tötterman AM; Pelle B
Arch Dis Child; 2019 Sep; 104(9):900-905. PubMed ID: 31201156
[TBL] [Abstract][Full Text] [Related]
12. Crowdfunding for Personalized Medicine Research.
Fumagalli DC; Gouw AM
Yale J Biol Med; 2015 Dec; 88(4):413-4. PubMed ID: 26604866
[TBL] [Abstract][Full Text] [Related]
13. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
Kumar Kakkar A; Dahiya N
Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
[TBL] [Abstract][Full Text] [Related]
14. [The pharmacist, rare diseases and orphan medicines].
Nagore Induráin C; Lacalle E; Arteche L
An Sist Sanit Navar; 2008; 31 Suppl 2():127-43. PubMed ID: 18953376
[TBL] [Abstract][Full Text] [Related]
15. Pay-to-participate funding schemes in human cell and tissue clinical studies.
Sipp D
Regen Med; 2012 Nov; 7(6 Suppl):105-11. PubMed ID: 23210821
[TBL] [Abstract][Full Text] [Related]
16. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
Pariser AR; Xu K; Milto J; Coté TR
Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
[TBL] [Abstract][Full Text] [Related]
17. How some patients in new-drug trials can get cut off.
Anand G
Wall St J (East Ed); 2003 Dec; ():A1, A11. PubMed ID: 14971381
[No Abstract] [Full Text] [Related]
18. Crowdfunding drug development: the state of play in oncology and rare diseases.
Dragojlovic N; Lynd LD
Drug Discov Today; 2014 Nov; 19(11):1775-1780. PubMed ID: 24973645
[TBL] [Abstract][Full Text] [Related]
19. Ethical issues regarding fee-for-service-funded research within a complementary medicine context.
Evans S; Block JB
J Altern Complement Med; 2001 Dec; 7(6):697-702. PubMed ID: 11822618
[TBL] [Abstract][Full Text] [Related]
20. Drug discovery and development for Huntington's disease - an orphan indication with high medical need.
Heitz F; La Rosa S; Gonzalez-Couto E; Gaviraghi G; Terstappen GC
IDrugs; 2008 Sep; 11(9):653-60. PubMed ID: 18763216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
